Anavex Lf SC (AVXL) Stock Price, Quote & News

Company Profile

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Al...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 689 3939

Website: www.anavex.com

Address:

630 5th Avenue, 20th Floor, New York, United States

PaulLaurent Nov. 17 at 7:31 AM

🔥 Short Squeeze Radar (ORTEX scores) — This Week $FLWS – 78,35/100. Elevated setup; watch borrow fees, locate tightness, and VWAP/pivot reclaims. $AVXL – 92,74/100. Very high squeeze risk; quick trims into spikes and tight risk on fades. $HIMS – 68,46/100. Mid-tier; needs volume expansion and clean reclaim to trigger. $CYCU – 76,05/100. Thin-float profile; monitor borrow dynamics and persistence above VWAP. $KSS – 66,39/100. Theme and headline sensitive; look for higher-low structure and liquidity pockets. Plan: Focus on VWAP/pivot reclaims, scale into strength on clean squeezes, and keep stops tight if borrow loosens or momentum stalls.

0 · Reply

Jjstubyjeong Nov. 17 at 7:29 AM

$AVXL Fasten your seatbelt folks, massive dilution coming after rejection🤣. This will make SP down to 1$

1 · Reply

homerromer Nov. 17 at 4:46 AM

$AVXL Here are the types of re-analyses that have historically been the most successful at reversing a negative CHMP opinion during a re-examination. These patterns come from public EMA assessment reports of medicines that ultimately won approval after initially receiving a negative opinion. ✅ 1. Clarifying Statistical Methodology This is the #1 most successful strategy. Many initial negative opinions come from: Misunderstandings of statistical models Disagreements about missing-data handling Not clearly justifying multiplicity control or hierarchy Inconsistent population definitions Successful re-analyses include: Re-running analyses using the CHMP-preferred statistical model Demonstrating robustness across multiple imputation strategies Providing clearer justification for the analysis hierarchy Harmonizing ITT and per-protocol definitions ✨ The key: Show that regardless of analytic method, the drug still meets efficacy criteria.

2 · Reply

History101 Nov. 17 at 4:20 AM

$AVXL the FDA is better now under RFK Jr but still too much corruption. imo No way will the FDA approve blarc as is. our best shot is EMA and we need to wait for the next EMA steps to be completed then hopefully we will have conditional approval.

1 · Reply

homerromer Nov. 17 at 4:20 AM

$AVXL I am still trying to figure out if Anavex can submit all of the OLE data? Any thoughts on how to interpret this? Can New Data Be Submitted During Re-examination? No — NEW clinical or pre-clinical data that wasn’t part of the original submission is not allowed. However, some important nuances: ❌ Not allowed You cannot submit: New clinical trial results New efficacy or safety data New patient cohorts New endpoints or analyses that did not exist at the time of the original submission ✔️ Allowed You can submit: Re-analyses of data already in the original dossier. New statistical analyses performed on the original data. Clarifications of methodology Additional explanations responding to CHMP concerns New risk-management strategies (if based on existing data) Updated manufacturing info (if it doesn’t fundamentally change the product) ➤ Edge case: Supplemental data You can submit supportive scientific literature that helps interpret previously submitted data.

1 · Reply

Mricess Nov. 17 at 4:09 AM

$AVXL how about conditional EmA approval for ABCLEAR cohorts pending confirmatory US trial needed to secure FDA approval. Win Win?

0 · Reply

Betting2024 Nov. 17 at 4:05 AM

$AVXL do we have a successful phase3 RETT trial already? I think the FDA said they would like to approve the drug later for use on adolescent together. But since we do have a successful phase3 trial for adults, why would the company ask FDA to approve the drug for adults only for now ?

1 · Reply

StocktwitsNews Nov. 17 at 4:00 AM

Anavex Retail Traders See Silver Lining In EMA Committee Postpones Alzheimer’s Drug Verdict: Delay 'Actually A Positive Sign' $AVXL https://stocktwits.com/news/equity/markets/anavex-retail-traders-see-silver-lining-in-ema-committee-postpones-alzheimer-s-drug-verdict/cLPkSk4REII

0 · Reply

Alex1710 Nov. 17 at 3:29 AM

$AVXL I feel sorry for all of us, I guess we're all under water and I feel sorry for Dr. Gabelle she seems so human goodness.

0 · Reply

redbugs Nov. 17 at 3:25 AM

$AVXL Missling owes us a conference call now.

0 · Reply

Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease

Oct 29, 2025, 7:30 AM EDT - 18 days ago

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group

Oct 10, 2025, 7:30 AM EDT - 5 weeks ago

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care'

Oct 2, 2025, 1:40 PM EDT - 6 weeks ago

Anavex: ANAVEX 3-71 Could Potentially Offer Disease-Modifying Effects For Schizophrenia

Oct 2, 2025, 7:35 AM EDT - 6 weeks ago

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

Oct 2, 2025, 7:30 AM EDT - 6 weeks ago

Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Sep 30, 2025, 8:30 AM EDT - 6 weeks ago

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial

Sep 9, 2025, 7:30 AM EDT - 2 months ago

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial

Sep 2, 2025, 7:30 AM EDT - 2 months ago

Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025

Aug 26, 2025, 7:30 AM EDT - 2 months ago

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine

Aug 20, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease

Aug 12, 2025, 10:38 AM EDT - 3 months ago

Anavex Life Sciences Corp. (AVXL) Q3 2025 Earnings Call Transcript

Aug 12, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update

Aug 5, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025

Jul 31, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

May 15, 2025, 8:49 PM EDT - 6 months ago

Does Anavex's Alzheimer's Drug Actually Confer Benefit?

May 15, 2025, 12:21 PM EDT - 6 months ago

The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)

May 14, 2025, 7:30 AM EDT - 6 months ago

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

May 13, 2025, 9:25 AM EDT - 6 months ago

Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript

May 13, 2025, 7:30 AM EDT - 6 months ago

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

May 6, 2025, 7:30 AM EDT - 6 months ago

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

May 1, 2025, 7:30 AM EDT - 7 months ago

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Apr 30, 2025, 7:30 AM EDT - 7 months ago

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

Apr 23, 2025, 7:30 AM EDT - 7 months ago

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

Apr 21, 2025, 7:30 AM EDT - 7 months ago

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East

Apr 5, 2025, 11:30 AM EDT - 8 months ago

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

Mar 31, 2025, 7:30 AM EDT - 8 months ago

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

Feb 24, 2025, 7:30 AM EST - 9 months ago

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

Feb 14, 2025, 6:02 PM EST - 9 months ago

Anavex: Looking At Different Statistical Approaches Before EMA Opinion

Feb 12, 2025, 3:13 PM EST - 9 months ago

Anavex: Further Validation Of Blarcamesine With Schizophrenia Data In 2025

Feb 12, 2025, 9:59 AM EST - 9 months ago

Anavex Life Sciences Corp. (AVXL) Q1 2025 Earnings Call Transcript

Feb 12, 2025, 7:30 AM EST - 9 months ago

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

Feb 5, 2025, 7:30 AM EST - 10 months ago

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

Jan 27, 2025, 7:30 AM EST - 10 months ago

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

Jan 15, 2025, 7:30 AM EST - 10 months ago

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease

Jan 13, 2025, 7:30 AM EST - 10 months ago

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients

Jan 12, 2025, 11:21 AM EST - 11 months ago

Playing The Odds Of Anavex Alzheimer's Drug Approval

Jan 6, 2025, 7:30 AM EST - 11 months ago

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 27, 2024, 7:30 AM EST - 11 months ago

Anavex Life Sciences: Jumping In On-Time Ahead Early Alzheimer's Decision

Dec 26, 2024, 10:31 AM EST - 11 months ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA PYPD

Dec 24, 2024, 8:50 AM EST - 11 months ago

Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis

Dec 23, 2024, 10:23 AM EST - 11 months ago

Anavex Life Sciences Corp. (AVXL) Q4 2024 Earnings Call Transcript

Dec 23, 2024, 7:30 AM EST - 11 months ago

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

Dec 23, 2024, 7:00 AM EST - 11 months ago

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease

Dec 16, 2024, 7:30 AM EST - 11 months ago

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

Dec 9, 2024, 7:30 AM EST - 1 year ago

Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference

Dec 2, 2024, 7:30 AM EST - 1 year ago

Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

Nov 26, 2024, 7:30 AM EST - 1 year ago

Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMA

Nov 25, 2024, 7:30 AM EST - 1 year ago

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal

PaulLaurent Nov. 17 at 7:31 AM

0 · Reply

Jjstubyjeong Nov. 17 at 7:29 AM

$AVXL Fasten your seatbelt folks, massive dilution coming after rejection🤣. This will make SP down to 1$

1 · Reply

homerromer Nov. 17 at 4:46 AM

2 · Reply

History101 Nov. 17 at 4:20 AM

1 · Reply

homerromer Nov. 17 at 4:20 AM

1 · Reply

Mricess Nov. 17 at 4:09 AM

$AVXL how about conditional EmA approval for ABCLEAR cohorts pending confirmatory US trial needed to secure FDA approval. Win Win?

0 · Reply

Betting2024 Nov. 17 at 4:05 AM

1 · Reply

StocktwitsNews Nov. 17 at 4:00 AM

0 · Reply

Alex1710 Nov. 17 at 3:29 AM

$AVXL I feel sorry for all of us, I guess we're all under water and I feel sorry for Dr. Gabelle she seems so human goodness.

0 · Reply

redbugs Nov. 17 at 3:25 AM

$AVXL Missling owes us a conference call now.

0 · Reply

Bio_Oko Nov. 17 at 3:14 AM

$AVXL alex1710 block me. I don’t blok anybody.

1 · Reply

Bio_Oko Nov. 17 at 2:41 AM

$AVXL oh! Thank you very much. Missling beast me by country mile, I can only hope to that astute as he is.

1 · Reply

Alex1710 Nov. 17 at 2:39 AM

$AVXL I think it should be you, with all your knowledge.

0 · Reply

Bio_Oko Nov. 17 at 2:39 AM

$AVXL wake up, people! Without Missling Blarcamesine would either be sold for pennies on the dollars or would become a failed drug and then would be saved by big pharma. It is Missling or bust✌️

2 · Reply

Alex1710 Nov. 17 at 2:38 AM

$AVXL We need a real entrepreneur that knows Wall Street and will fear the sharks. They bite , we bite.

0 · Reply

Bio_Oko Nov. 17 at 2:32 AM

$AVXL I haven’t heard greater BS. Compare other CEO in the field small biotech with Missling. I read papers on AD and I realized that Missling is the only one science based there are bean counters. He real knows AD science. This man is a genius. Both in understanding science and finance. Yes, he is not the best smooth bull sh**er like most American CEOs but he leads as the best CEO. I can quip since I am 1/8 German I can understand him better than most Americans.

4 · Reply

Alex1710 Nov. 17 at 2:24 AM

$AVXL It is time for a new leadership, a good communicator, someone with a vaste contact network with proven track records. Someone credible and recognize in the financial community. We have enough Phd in this management team.

0 · Reply

Bio_Oko Nov. 17 at 2:22 AM

$AVXL so what the members understand? We only know that there is “negative trend”. It could be 2 ,3 maybe 8, may be 10 or may be 100. The statement so vague that might only come from some great manipulators. Whatever happens later CHMP covered its ass legally. Now, it can request more info and approve or deny with equal plausibility. All options open. During the Cold War there was dearth of info about Soviet politics. So people analyzed and parsed language and public appearances. This shit is similar.

2 · Reply

Alex1710 Nov. 17 at 2:08 AM

$AVXL Yes you're the only one that understand everything even more that the CHMP members committee.

0 · Reply

Bio_Oko Nov. 17 at 2:05 AM

$AVXL people do not understands fundamental reasons behind science. Fundamentally, in OLE Anavex proved that the impossible could happen to patients who otherwise should all severely decline. The odds ratio went into double digits territory. The Big Pharma knows this and if after the drug. Why in school they teach you to derive formulas and definition because everything is driven in science by logic. If you don’t understand that logic you only mince words.

1 · Reply

sloshy665 Nov. 17 at 2:00 AM

$AVXL calling folks dumb but being posting on this board for (awhile) guess this bag holder is down a ton and has a avg of $10+ ouchy. Buddie got scammed by his CEO 😂😂😂😂

0 · Reply

Alex1710 Nov. 17 at 1:56 AM

$AVXL As we say, at the end of the day Anavex is in front of challenging time, cash is limited, sharks are all around, the process with the EMA is totally uncertain. Next move has to be the right one.

0 · Reply

Market Cap	313.08M
Revenue (ttm)	0.00
Net Income (ttm)	-43.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	22,984,199
Avg Vol	1,934,138
Day's Range	N/A - N/A
Shares Out	85.89M
Stochastic %K	16%
Beta	0.92
Analysts	Sell
Price Target	$44.00